Conatus Pharmaceuticals Inc.

There have been numerous deals centered on metabolic dysfunction-associated steatohepatitis (MASH) over roughly the past decade, but the 14 May deal in which GSK acquired Boston Pharmaceuticals’ Phase

Since it has become difficult for many biopharmaceutical companies to raise money during the past year and a half, several firms have been forced to cut costs to make remaining cash balances last long

Zydus Cadila flagship firm Cadila Healthcare Ltd. has received marketing approval from the Drugs Controller General of India for its new chemical entity saroglitazar, to treat non-cirrhotic, non-al

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Histogen’s Regenerative Medi